Status:
COMPLETED
Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
Lead Sponsor:
Piedmont Healthcare
Collaborating Sponsors:
ViraCor Laboratories
Conditions:
Kidney Transplant; Complications
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients...
Detailed Description
Kidney transplant patients that are cytomegalovirus (CMV) seronegative (IgG negative) at time of transplant and receive a graft from a donor that is CMV seropositive (IgG positive) are at increased ri...
Eligibility Criteria
Inclusion
- Able to provide consent
- Kidney Transplant Recipients
- Classified as CMV high risk at time of transplant (donor CMV IgG positive and recipient CMV IgG negative)
Exclusion
- none
Key Trial Info
Start Date :
January 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT05238220
Start Date
January 4 2021
End Date
June 30 2022
Last Update
November 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Piedmont Atlanta Hospital
Atlanta, Georgia, United States, 30309